Cargando…

Tailored lipopeptide surfactants as potentially effective drugs to treat SARS-CoV-2 infection

Finding effective drugs to treat SARS-CoV-2 infection as a complementary step to the extensive vaccination is of the great importance to overcome the current pandemic situation. It has been shown that some bio-active unsaturated fatty acids such as Arachidonic Acid (AA) can reduce the infection seve...

Descripción completa

Detalles Bibliográficos
Autor principal:	Biria, Davoud
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482169/ https://www.ncbi.nlm.nih.gov/pubmed/36157252 http://dx.doi.org/10.1016/j.mehy.2022.110948

Ejemplares similares

Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern
por: Schmitz, Katharina S., et al.
Publicado: (2022)

Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides
por: Zhu, Yuanmei, et al.
Publicado: (2022)

Novel Synthetic Lipopeptides as Potential Mucosal Adjuvants Enhanced SARS-CoV-2 rRBD-Induced Immune Response
por: Mao, Ling, et al.
Publicado: (2022)

Cationic Surfactants as Disinfectants against SARS-CoV-2
por: Karamov, Eduard V., et al.
Publicado: (2022)

Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets
por: de Vries, Rory D., et al.
Publicado: (2020)

Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets
por: de Vries, Rory D., et al.
Publicado: (2021)

Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection
por: Lan, Qiaoshuai, et al.
Publicado: (2021)

Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach
por: D’Abramo, Alessandra, et al.
Publicado: (2021)

Cyclic lipopeptides as membrane fusion inhibitors against SARS-CoV-2: New tricks for old dogs
por: Shekunov, Egor V., et al.
Publicado: (2023)

Reduced DMPC and PMPC in lung surfactant promote SARS-CoV-2 infection in obesity
por: Du, Kang, et al.
Publicado: (2022)

Surfactant protein D (SP-D) as a biomarker of SARS-CoV-2 infection
por: Salvioni, Lucia, et al.
Publicado: (2022)

Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants
por: Yu, Danwei, et al.
Publicado: (2021)

Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-2
por: Zhu, Yuanmei, et al.
Publicado: (2023)

Toll-like receptor 2 activation depends on lipopeptide shedding by bacterial surfactants
por: Hanzelmann, Dennis, et al.
Publicado: (2016)

Defensins: Therapeutic molecules with potential to treat SARS-CoV-2 infection
por: Banu, Sarena, et al.
Publicado: (2022)

Surfactants – Compounds for inactivation of SARS-CoV-2 and other enveloped viruses
por: Simon, Miriam, et al.
Publicado: (2021)

Adsorption of Pulmonary and Exogeneous Surfactants on SARS-CoV-2 Spike Protein
por: Santo, Kolattukudy P., et al.
Publicado: (2023)

Surfactants tailored by the class Actinobacteria
por: Kügler, Johannes H., et al.
Publicado: (2015)

Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection
por: Sacher, Frederic, et al.
Publicado: (2020)

Potential repurposed SARS-CoV-2 (COVID-19) infection drugs
por: Abuo-Rahma, Gamal El-Din A., et al.
Publicado: (2020)

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron
por: Zhu, Yuanmei, et al.
Publicado: (2022)

Efficient delipidation of a recombinant lung surfactant lipopeptide analogue by liquid-gel chromatography
por: Basabe-Burgos, Oihana, et al.
Publicado: (2019)

SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
por: Elshabrawy, Hatem A.
Publicado: (2020)

Comparative transcriptome analysis of SARS-CoV, MERS-CoV, and SARS-CoV-2 to identify potential pathways for drug repurposing
por: Krishnamoorthy, Pandikannan, et al.
Publicado: (2021)

Novel Cyclic Lipopeptides Fusaricidin Analogs for Treating Wound Infections
por: Gil, Joel, et al.
Publicado: (2021)

Natural products as a source of novel drugs for treating SARS-CoV2 infection
por: Isidoro, Ciro, et al.
Publicado: (2022)

QTc interval prolongation in patients infected with SARS-CoV-2 and treated with antiviral drugs()()
por: Esmel-Vilomara, Roger, et al.
Publicado: (2022)

Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021)

Phytochemicals against SARS-CoV as potential drug leads
por: Swain, Shasank Sekhar, et al.
Publicado: (2021)

Pulmonary surfactant itself must be a strong defender against SARS-CoV-2
por: Takano, Hideyuki
Publicado: (2020)

Antiseptic Polymer–Surfactant Complexes with Long-Lasting Activity against SARS-CoV-2
por: Molchanov, Vyacheslav S., et al.
Publicado: (2022)

Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection
por: Rao, Praveen P. N., et al.
Publicado: (2021)

Methods matter – Tailoring SARS-CoV-2 antibody targets to vaccination status
por: Rapp, Alexandra R., et al.
Publicado: (2021)

SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses
por: Zhu, Yuanmei, et al.
Publicado: (2021)

Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
por: Patocka, Jiri, et al.
Publicado: (2021)

Anaesthesia-related drugs and SARS-CoV-2 infection
por: Hirota, Kazuyoshi, et al.
Publicado: (2021)

SARS-CoV-2 Infection in Spondyloarthritis Patients Treated With Biotechnological Drugs: A Study on Serology
por: Ortolan, Augusta, et al.
Publicado: (2021)

SARS-CoV-2 Infection is Effectively Treated and Prevented by EIDD-2801
por: Wahl, Angela, et al.
Publicado: (2021)

SARS-CoV, MERS-CoV and SARS-CoV-2 infections in pregnancy and fetal development
por: de Souza Silva, Guilherme Antonio, et al.
Publicado: (2020)

Imaging findings in coronavirus infections: SARS-CoV, MERS-CoV, and SARS-CoV-2
por: Franquet, Tomas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ofep6r9o0edjoutr14pagp250h